Key facts
- This page summarizes Donald A. Kalkofen's Form 4 filing for Protagonist Therapeutics, Inc (PTGX).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 17 Feb 2022, 18:26.
Donald A. Kalkofen - 15 Feb 2022 Form 4 Insider Report for Protagonist Therapeutics, Inc (PTGX)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- PTGX
- Reported as of
- 15 Feb 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 17 Feb 2022, 18:26:56 UTC
- Next SEC filing
- 26 May 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Donald A. Kalkofen
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Donald A. Kalkofen filed Form 4 for Protagonist Therapeutics, Inc (PTGX) on 17 Feb 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PTGX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +7,500
- Change %
- +68%
- Price
- $0.000000
- Shares after
- 18,521
- Date
- 15 Feb 2022
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PTGX
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +45,000
- Change %
- Price
- $0.000000
- Shares after
- 45,000
- Date
- 15 Feb 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 45,000
- Exercise price
- $28.73
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents grant of restricted stock units payable solely in common stock that will vest in three annual installments on February 15, 2023, 2024 and 2025.
Footnote F2
Includes an aggregate of 635 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2021.
Footnote F3
The stock option vests in 48 equal monthly installments following the date of grant.